Product/Composition:- | Pravastatin |
---|---|
Strength:- | 10 mg, 20 mg, 40 mg, 80 mg |
Form:- | Tablet |
Reference Brands:- | Pravachol(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Pravastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver. It lowers LDL cholesterol, boosts HDL, and decreases cardiovascular risk. Benefits include preventing heart attacks, strokes, and atherosclerosis, enhancing long-term heart health, improving lipid profiles, and supporting overall cardiovascular disease prevention.
Pravastatin tablets, marketed as Pravachol, are approved in the US by the FDA and in the EU via EMA for managing hyperlipidemia and preventing cardiovascular disease. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical trial and manufacturing data, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring accurate regional compliance supports timely approval, safe use, and worldwide availability of pravastatin tablets, helping millions worldwide lower LDL cholesterol and mitigate cardiovascular risk effectively.